ClassID:

109196

C12N2310/3515 - page 2 - CPC Classification

Classification description:

Structure or type of the nucleic acid; Chemical structure; Nature of the modification; Conjugate Lipophilic moiety, e.g. cholesterol

Recent Application in this class:
#301
20220348915
2022-11-03

GNAQ targeted dsRNA compositions and methods for inhibiting expression

#302
20220340903
2022-10-27

TARGETING RLIM TO MODULATE BODY WEIGHT AND OBESITY

#303
20220333104
2022-10-20

TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES

#304
20220324984
2022-10-13

NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF

#305
20220323606
2022-10-13

Targeting technology to selectively express mRNAs in cardiomyocytes while avoiding stimulation of cardiac fibroblasts

#306
20220307024
2022-09-29

DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM

#307
20220307019
2022-09-29

DOUBLE-STRANDED NUCLEIC ACID COMPLEX AND USE THEREOF

#308
20220306676
2022-09-29

Oligonucleotide compositions and methods of making the same

#309
20220305045
2022-09-29

SERUM AMYLOID P COMPONENT (APCS) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#310
20220275375
2022-09-01

COMPOSITIONS AND METHODS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA

#311
20220275366
2022-09-01

RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA)

#312
20220275365
2022-09-01

COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION

#313
20220251554
2022-08-11

OLIGONUCLEOTIDE COMPOUNDS FOR TARGETING HUNTINGTIN MRNA

#314
20220243202
2022-08-04

NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF PROS1 IN A CELL

#315
20220243199
2022-08-04

Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene

#316
20220241317
2022-08-04

Conjugation of lipophilic albumin-binding moiety to RNA for improved carrier-free in vivo pharmacokinetics and gene silencing

#317
20220235361
2022-07-28

RNAi Inhibition of Alpha-ENaC Expression

#318
20220235358
2022-07-28

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

#319
20220233717
2022-07-28

NUCLEIC ACID CARRIER AND METHOD FOR ADMINISTERING NUCLEIC ACID

#320
20220228151
2022-07-21

Carboxypeptidase B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#321
20220213473
2022-07-07

COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE

#322
20220195434
2022-06-23

Oversubscription scheduling

#323
20220186229
2022-06-16

METHODS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF CYP27A1

#324
20220186213
2022-06-16

DIRECT OLIGONUCLEOTIDE SYNTHESIS ON CELLS AND BIOMOLECULES

#325
20220175816
2022-06-09

AIM2 INHIBITORS AND USES THEREOF

#326
20220160633
2022-05-26

COMPOSITIONS FOR DELIVERY OF CODON-OPTIMIZED MRNA

#327
20220155716
2022-05-19

SERPINA1 SIRNAS: COMPOSITIONS OF MATTER AND METHODS OF TREATMENT

#328
20220145302
2022-05-12

TARGETS AND METHODS FOR TREATING EPSTEIN-BARR VIRUS MEDIATED NEURODEGENERATION

#329
20220143049
2022-05-12

A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER

#330
20220133900
2022-05-05

Compositions and methods of treating muscle atrophy and myotonic dystrophy

#331
20220127618
2022-04-28

KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#332
20220127617
2022-04-28

TREATMENT OF CNS INJURY WITH RNAi THERAPEUTICS

#333
20220127615
2022-04-28

CORONAVIRUS IRNA COMPOSITIONS AND METHODS OF USE THEREOF

#334
20220127608
2022-04-28

P-ethoxy nucleic acids for STAT3 inhibition

#335
20220125823
2022-04-28

EXTRAHEPATIC DELIVERY

#336
20220119815
2022-04-21

ANGIOPOIETIN-LIKE 3 (ANGPTL3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF

#337
20220117999
2022-04-21

PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#338
20220112505
2022-04-14

RNAi Inhibition of Alpha-ENaC Expression

#339
20220098581
2022-03-31

Methods for Oral Delivery of Oligonucleotides

#340
20220090074
2022-03-24

HNF4a saRNA compositions and methods of use

#341
20220087531
2022-03-24

RNA INTERFERENCE COMPOSITIONS AND METHODS FOR MALIGNANT TUMORS

#342
20220081689
2022-03-17

Compounds and Methods for Use in Dystrophin Transcript

#343
20220079973
2022-03-17

RNAi agents for Hepatitis B virus infection

#344
20220073929
2022-03-10

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

#345
20220073928
2022-03-10

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

#346
20220073927
2022-03-10

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

#347
20220073926
2022-03-10

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

#348
20220073925
2022-03-10

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

#349
20220073924
2022-03-10

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

#350
20220073914
2022-03-10

COMPOUNDS AND METHODS FOR MODULATION OF SMN2

#351
20220062434
2022-03-03

Compositions and methods of treating muscle atrophy and myotonic dystrophy

#352
20220056069
2022-02-24

IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE

#353
20220049253
2022-02-17

COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF APOLIPOPROTEIN C-III (APOC3) GENES

#354
20220042012
2022-02-10

INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN, ACID LABILE SUBUNIT (IGFALS) AND INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#355
20220040323
2022-02-10

Compositions and methods of treating muscle atrophy and myotonic dystrophy

#356
20220040322
2022-02-10

Compositions and methods of treating muscle atrophy and myotonic dystrophy

#357
20220040276
2022-02-10

Compositions and methods for delivery of biomacromolecule agents

#358
20220033825
2022-02-03

POLYNUCLEOTIDE AGENTS TARGETING PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) AND METHODS OF USE THEREOF

#359
20220033817
2022-02-03

Targeting Ligands

#360
20220025376
2022-01-27

Antisense oligomers targeting PCSK9

#361
20220025370
2022-01-27

OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE

#362
20220025367
2022-01-27

NOVEL RNA COMPOSITIONS AND METHODS FOR INHIBITING ANGPTL8

#363
20220023429
2022-01-27

CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE

#364
20220023427
2022-01-27

Lipids and compositions for the delivery of therapeutics

#365
20220017898
2022-01-20

OLIGONUCLEOTIDES CONJUGATES COMPRISING 7'-5'-ALPHA-ANOMERIC-BICYCLIC SUGAR NUCLEOSIDES

#366
20220008550
2022-01-13

Compositions and methods of treating muscle atrophy and myotonic dystrophy

#367
20210403917
2021-12-30

COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE

#368
20210403914
2021-12-30

Specific siRNA molecules, composition and use thereof for the treatment of triple negative breast cancer

#369
20210402007
2021-12-30

POLYNUCLEOTIDE AGENTS TARGETING HYDROXYACID OXIDASE (GLYCOLATE OXIDASE, HAO1) AND METHODS OF USE THEREOF

#370
20210395734
2021-12-23

COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION

#371
20210388360
2021-12-16

COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF PROTEIN C (PROC) GENES

#372
20210388355
2021-12-16

Dosages and methods for delivering lipid formulated nucleic acid molecules

#373
20210380986
2021-12-09

RNA DRUGS AND METHOD OF TREATING AGE-RELATED DISEASE

#374
20210380985
2021-12-09

17ß-Hydroxysteroid Dehydrogenase Type 13 (HSD17B13) iRNA Compositions And Methods Of Use Thereof

#375
20210363524
2021-11-25

OLIGONUCLEOTIDES FOR SNCA MODULATION

#376
20210363518
2021-11-25

MODIFIED GUIDE RNAS FOR CRISPR GENOME EDITING

#377
20210355491
2021-11-18

OLIGONUCLEOTIDES FOR MSH3 MODULATION

#378
20210348169
2021-11-11

Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1

#379
20210348166
2021-11-11

IMMUNOTHERAPY OF CANCER

#380
20210348162
2021-11-11

Compositions and methods for inhibiting expression of the LECT2 gene

#381
20210340540
2021-11-04

CHIMERIC DOUBLE-STRANDED NUCLEIC ACID

#382
20210340538
2021-11-04

Compositions and methods for prevention of bladder fibrosis

#383
20210340533
2021-11-04

Oligonucleotides for tissue specific gene expression modulation

#384
20210317460
2021-10-14

Oligonucleotides for PRNP modulation

#385
20210317451
2021-10-14

Compositions and methods for modulating neuronal excitability and motor behavior

#386
20210315918
2021-10-14

Compounds and Methods for Modulation of Transcript Processing

#387
20210292768
2021-09-23

COMPOSITIONS AND AGENTS AGAINST NONALCOHOLIC STEATOHEPATITIS

#388
20210285001
2021-09-16

Long double-stranded RNA for RNA interference

#389
20210284999
2021-09-16

Application of microRNA-210 inhibitor in preparation of drugs for treating inflammatory skin diseases

#390
20210269807
2021-09-02

USE OF A JANUS KINASE INHIBITOR AND A TELOMERASE INHIBITOR FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS

#391
20210269806
2021-09-02

IL-1 BETA TARGETING SPHERICAL NUCLEIC ACIDS

#392
20210269797
2021-09-02

METHODS AND COMPOSITIONS FOR TARGETING PD-L1

#393
20210261968
2021-08-26

RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS

#394
20210261964
2021-08-26

LIPID PARTICLE CONTAINING A-TYPE CpG OLIGODEOXYNUCLEOTIDE

#395
20210254063
2021-08-19

SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#396
20210238601
2021-08-05

Oligonucleotide Conjugates

#397
20210222170
2021-07-22

Von Willebrand Factor (VWF)-targeting agents and methods of using the same

#398
20210222166
2021-07-22

LNA BASED NANODEVICE

#399
20210207140
2021-07-08

Non-liposomal systems for nucleic acid delivery

#400
20210207137
2021-07-08

RNA-INTERFERENCE-INDUCING NUCLEIC ACID MOLECULE ABLE TO PENETRATE INTO CELLS, AND USE THEREFOR

#401
20210198661
2021-07-01

Methods for extending polynucleotides

#402
20210189435
2021-06-24

System for DNA editing and uses thereof

#403
20210189433
2021-06-24

Agents for improved delivery of nucleic acids to eukaryotic cells

#404
20210189398
2021-06-24

AMPHIREGULIN GENE-SPECIFIC DOUBLE-STRANDED OLIGONUCLEOTIDE AND COMPOSITION FOR PREVENTING AND TREATING FIBROSIS-RELATED DISEASES AND RESPIRATORY DISEASES, COMPRISING SAME

#405
20210189394
2021-06-24

Targeting ligands for therapeutic compounds

#406
20210189391
2021-06-24

Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof

#407
20210187116
2021-06-24

Compositions and methods of treating muscle atrophy and myotonic dystrophy

#408
20210179720
2021-06-17

Nucleic acid-polypeptide compositions and uses thereof

#409
20210177884
2021-06-17

COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#410
20210171955
2021-06-10

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

#411
20210171954
2021-06-10

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

#412
20210170020
2021-06-10

Immunostimulatory compositions

#413
20210169917
2021-06-10

Conjugated Antisense Compounds for Use in Therapy

#414
20210163950
2021-06-03

TREATMENT OF ANGIOPOIETIN LIKE 7 (ANGPTL7) RELATED DISEASES

#415
20210163934
2021-06-03

BBB-crossing lipid ligand of hetero nucleic acid

#416
20210162053
2021-06-03

NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS

#417
20210147849
2021-05-20

REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS

#418
20210147840
2021-05-20

SiRNAs with vinylphosphonate at the 5′ end of the antisense strand

#419
20210145745
2021-05-20

Targeted delivery of therapeutic agents to human adipocytes

#420
20210139894
2021-05-13

Treatment of Fuchs' endothelial corneal dystrophy

#421
20210139893
2021-05-13

G-quadruplex-containing antisense oligonucleotides

#422
20210130825
2021-05-06

Ischemic-lesion-site-specific gene therapy

#423
20210130823
2021-05-06

COMPOSITIONS AND METHODS

#424
20210115442
2021-04-22

O-METHYL RICH FULLY STABILIZED OLIGONUCLEOTIDES

#425
20210113603
2021-04-22

MicroRNA (miRNA) and Downstream Targets for Diagnostic and Therapeutic Purposes

#426
20210108205
2021-04-15

MicroRNA Compounds and Methods for Modulating MIR-122

#427
20210108203
2021-04-15

Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof

#428
20210108200
2021-04-15

BRANCHED LIPID CONJUGATES OF siRNA FOR SPECIFIC TISSUE DELIVERY

#429
20210106538
2021-04-15

Compositions and methods for delivery of biomacromolecule agents

#430
20210101875
2021-04-08

Aminoalcohol lipidoids and uses thereof

#431
20210100829
2021-04-08

RNAi agents for hepatitis B virus infection

#432
20210093736
2021-04-01

Methods for Preventing Cardiovascular Events Through Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Reduction

#433
20210093568
2021-04-01

LOADING OF EXTRACELLULAR VESICLES THROUGH IMPARTING OF MECHANICAL SHEAR

#434
20210087566
2021-03-25

Compositions and methods for modulating apolipoprotein (a) expression

#435
20210085793
2021-03-25

Branched oligonucleotides

#436
20210077520
2021-03-18

Vesicles comprising a PTEN inhibitor and uses of same

#437
20210071181
2021-03-11

PHARMACEUTICAL COMPOSITION

#438
20210062195
2021-03-04

RNA interference in ocular indications

#439
20210060168
2021-03-04

Asialoglycoprotein Receptor mediated delivery of therapeutically active conjugates

#440
20210054381
2021-02-25

Oligomers and oligomer conjugates

#441
20210047640
2021-02-18

COMPOSITIONS AND METHODS FOR TREATING HYPERTRIGLYCERIDEMIA

#442
20210041823
2021-02-11

SERPINA1 SIRNAS: COMPOSITIONS OF MATTER AND METHODS OF TREATMENT

#443
20210038519
2021-02-11

Lipid-derived neutral nanoparticles

#444
20210024926
2021-01-28

Fully stabilized asymmetric siRNA

#445
20210024923
2021-01-28

COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION

#446
20210023116
2021-01-28

TREATMENT OF CANCER BY SYSTEMIC ADMINISTRATION OF DBAIT MOLECULES

#447
20210017537
2021-01-21

Preparation and use of nanoparticle-doped RNA hydrogel targeting to triple negative breast cancer

#448
20210009994
2021-01-14

Direct oligonucleotide synthesis on cells and biomolecules

#449
20210008226
2021-01-14

Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety

#450
20210002640
2021-01-07

LIPOSOMAL SPHERICAL NUCLEIC ACID (SNA) CONSTRUCTS FOR SURVIVAL OF MOTOR NEURON (SMA) INHIBITORS

#451
20210002638
2021-01-07

Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereof

#452
20200407725
2020-12-31

Methods and compositions for macrophage polarization

#453
20200407724
2020-12-31

Targeted compositions

#454
20200405877
2020-12-31

Compositions and methods of treating muscle atrophy and myotonic dystrophy

#455
20200399640
2020-12-24

Treatment of angiopoietin like 7 (ANGPTL7) related diseases

#456
20200399338
2020-12-24

IL-15 conjugates and uses thereof

#457
20200392509
2020-12-17

Conjugated antisense compounds and their use

#458
20200392498
2020-12-17

POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS

#459
20200392490
2020-12-17

Compounds and methods for trans-membrane delivery of molecules

#460
20200385733
2020-12-10

Immunostimulatory oligonucleotides

#461
20200385726
2020-12-10

Oversubscription scheduling

#462
20200385721
2020-12-10

DELIVERING CRISPR THERAPEUTICS WITH LIPID NANOPARTICLES

#463
20200377893
2020-12-03

COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MUTANT EGFR GENE

#464
20200377889
2020-12-03

Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases

#465
20200370049
2020-11-26

Methods and compositions for treating cancer using peptide nucleic acid-based agents

#466
20200362341
2020-11-19

OLIGONUCLEOTIDES FOR TISSUE SPECIFIC APOE MODULATION

#467
20200362340
2020-11-19

Modulating apolipoprotein (a) expression

#468
20200345758
2020-11-05

Serum amyloid P component (APCS) iRNA compositions and methods of use thereof

#469
20200339996
2020-10-29

ANTI-TNF COMPOUNDS

#470
20200339989
2020-10-29

NUCLEIC ACID NANOSTRUCTURES WITH CORE MOTIFS

#471
20200339983
2020-10-29

Bioactive conjugates for oligonucleotide delivery

#472
20200339975
2020-10-29

Methods of polynucleotide preparation using multivalent cation salt compositions

#473
20200318119
2020-10-08

Compositions and Methods for Inhibiting Expression of the PCSK9 Gene

#474
20200318113
2020-10-08

POLYNUCLEOTIDE CONJUGATES AND USES THEREOF

#475
20200318109
2020-10-08

LNA-G process

#476
20200316201
2020-10-08

Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression

#477
20200308584
2020-10-01

Oligonucleotide compounds for targeting huntingtin mRNA

#478
20200308578
2020-10-01

RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality

#479
20200299698
2020-09-24

Xanthine dehydrogenase (XDH) IRNA compositions and methods of use thereof

#480
20200291405
2020-09-17

HEPATITIS D VIRUS (HDV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#481
20200291394
2020-09-17

CONJUGATION OF PEPTIDES TO SPHERICAL NUCLEIC ACIDS (SNAS) USING TRACELESS LINKERS

#482
20200283801
2020-09-10

Exosomal loading using hydrophobically modified oligonucleotides

#483
20200283766
2020-09-10

Compositions and Methods for Inhibiting Expression of Transthyretin

#484
20200277599
2020-09-03

Insulin-like growth factor binding protein, acid labile subunit (IGFALS) and insulin-like growth factor 1 (IGF-1) iRNA compositions and methods of use thereof

#485
20200270611
2020-08-27

GALNAC DERIVATIVES

#486
20200270609
2020-08-27

Single-Stranded RNAI Oligonucleotides Targeting APOC-III

#487
20200270605
2020-08-27

Dynamic pharmacokinetic-modifying anchors

#488
20200268879
2020-08-27

Amphiphilic oligodeoxynucleotide conjugates as adjuvant enhancers

#489
20200263176
2020-08-20

Compositions and Methods for Inhibition of Expression of Apolipoprotein C-III (APOC3) Genes

#490
20200255833
2020-08-13

Therapeutic compositions

#491
20200255827
2020-08-13

Stabilized HNF4A saRNA compositions and methods of use

#492
20200255826
2020-08-13

HNF4A saRNA compositions and methods of use

#493
20200248186
2020-08-06

Antisense oligomers targeting PCSK9

#494
20200239890
2020-07-30

Compositions and methods for inhibition of expression of protein C (PROC) genes

#495
20200239887
2020-07-30

Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene

#496
20200224201
2020-07-16

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

#497
20200224198
2020-07-16

COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION

#498
20200216844
2020-07-09

SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#499
20200215113
2020-07-09

CHEMICALLY MODIFIED OLIGONUCLEOTIDES

#500
20200199592
2020-06-25

siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis

#501
20200199591
2020-06-25

Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof

#502
20200190519
2020-06-18

Brush polymer-assisted compaction of oligonucleotides

#503
20200190511
2020-06-18

MICRO-RNA FAMILY THAT MODULATES FIBROSIS AND USES THEREOF

#504
20200181607
2020-06-11

TETRAMOLECULAR PARALLEL G-QUADRUPLEX-FORMING HYDROPHOBICALLY MODIFIED OLIGONUCLEOTIDES

#505
20200172909
2020-06-04

Ketohexokinase (KHK) iRNA compositions and methods of use thereof

#506
20200172908
2020-06-04

NANOCOMPOSITES FOR IMAGING AND DRUG DELIVERY

#507
20200157550
2020-05-21

RNAi inhibition of alpha-ENaC expression

#508
20200157548
2020-05-21

COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS

#509
20200140866
2020-05-07

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

#510
20200140864
2020-05-07

Hepatitis B virus (HBV) iRNA compositions and methods of use thereof

#511
20200138847
2020-05-07

Myostatin iRNA compositions and methods of use thereof

#512
20200131516
2020-04-30

Molecules and agents for treating hepatitis B virus

#513
20200123548
2020-04-23

TREATMENT OF ANGIOGENESIS-ASSOCIATED DISEASES USING RNA COMPLEXES THAT TARGET ANGPT2 AND PDGFB

#514
20200123547
2020-04-23

NUCLEIC ACID-BASED ASSEMBLY AND USES THEREOF

#515
20200123261
2020-04-23

NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF

#516
20200109405
2020-04-09

Treatment of atopic dermatitis and asthma using RNA complexes that target IL4Rα, TRPA1, or F2RL1

#517
20200080088
2020-03-12

APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#518
20200069720
2020-03-05

MicroRNA (miRNA) and Downstream Targets for Diagnostic and Therapeutic Purposes

#519
20200056175
2020-02-20

COMPOSITIONS AND METHODS FOR INHIBITIION OF EXPRESSION OF PROTEIN C (PROC) GENES

#520
20200040343
2020-02-06

Compositions and methods for the treatment of hypercholesterolemia

#521
20200040339
2020-02-06

P-ethoxy nucleic acids for STAT3 inhibition

#522
20200032293
2020-01-30

NUCLEIC ACID DELIVERY CARRIER, NUCLEIC ACID DELIVERY KIT, AND NUCLEIC ACID DELIVERY METHOD

#523
20200032268
2020-01-30

Treatment of CNS injury with RNAi therapeutics

#524
20200032258
2020-01-30

COMPLEMENT COMPONENT C5 IRNA COMPOSITIONS AND METHODS OF USE THEREOF

#525
20200031862
2020-01-30

LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS

#526
20200024605
2020-01-23

Oligomers and oligomer conjugates

#527
20200024599
2020-01-23

RNA interference for the treatment of gain-of-function disorders

#528
20200002701
2020-01-02

Reduced size self-delivering RNAI compounds

#529
20190367925
2019-12-05

Treatment of idiopathic pulmonary fibrosis using RNA complexes that target connective tissue growth factor

#530
20190367914
2019-12-05

Conjugated antisense compounds and their use

#531
20190365648
2019-12-05

Synthetic nanostructures including nucleic acids and/or other entities

#532
20190359984
2019-11-28

Compositions and methods for inhibiting gene expression of factor XII

#533
20190354055
2019-11-21

Serpina1 siRNAs: compositions of matter and methods of treatment

#534
20190352645
2019-11-21

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

#535
20190345498
2019-11-14

Modified iRNA agents

#536
20190345492
2019-11-14

Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases

#537
20190330626
2019-10-31

COMPOUNDS AND METHODS FOR USE IN DYSTROPHIN TRANSCRIPT

#538
20190323006
2019-10-24

COMPOUNDS AND METHODS FOR MODULATION OF SMN2

#539
20190321388
2019-10-24

Pharmaceutical compositions and methods for potentiating gene silencing

#540
20190321387
2019-10-24

COMPOUNDS AND METHODS FOR MODULATION OF TRANSCRIPT PROCESSING

#541
20190316137
2019-10-17

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

#542
20190309293
2019-10-10

Compositions and Methods for Inhibiting Expression of Transthyretin

#543
20190298847
2019-10-03

Compositions and methods of treating muscle atrophy and myotonic dystrophy

#544
20190292547
2019-09-26

RNAi agents for Hepatitis B virus infection

#545
20190292310
2019-09-26

SYNTHESIS OF HIGH DENSITY MOLECULAR DNA BRUSHES VIA ORGANIC-PHASE RING-OPENING METATHESIS (CO)POLYMERIZATION

#546
20190284561
2019-09-19

Methods and compositions for treating cancer using peptide nucleic acid-based agents

#547
20190284558
2019-09-19

Compositions and methods for inhibiting gene expression of alpha-1 AntiTrypsin

#548
20190284557
2019-09-19

DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES

#549
20190270996
2019-09-05

Chimeric double-stranded nucleic acid

#550
20190264230
2019-08-29

Agents for improved delivery of nucleic acids to eukaryotic cells

#551
20190264207
2019-08-29

Therapeutic compositions

#552
20190256849
2019-08-22

Targeting ligands

#553
20190249173
2019-08-15

METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS

#554
20190247507
2019-08-15

Branched oligonucleotides

#555
20190233826
2019-08-01

RNA interference in ocular indications

#556
20190233817
2019-08-01

Organic compositions to treat APOC3-related diseases

#557
20190225965
2019-07-25

Oligonucleotide compounds for targeting huntingtin mRNA

#558
20190218557
2019-07-18

INHIBITION OF PCSK9 THROUGH RNAI

#559
20190218553
2019-07-18

Von Willebrand Factor (VWF)—targeting agents and methods of using the same

#560
20190216845
2019-07-18

Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof

#561
20190211338
2019-07-11

Anti-TNF compounds

#562
20190211337
2019-07-11

Neutral nanotransporters

#563
20190211333
2019-07-11

Targeting Ligands For Therapeutic Compounds

#564
20190209604
2019-07-11

Oligonucleotides, compositions and methods thereof

#565
20190192681
2019-06-27

Nucleic acid-polypeptide compositions and uses thereof

#566
20190192435
2019-06-27

Lipid-derived neutral nanoparticles

#567
20190185855
2019-06-20

Conjugated oligonucleotides

#568
20190177729
2019-06-13

4'-phosphate analogs and oligonucleotides comprising the same

#569
20190177289
2019-06-13

Aminoalcohol lipidoids and uses thereof

#570
20190175506
2019-06-13

Loading of Extracellular Vesicles through Imparting of Mechanical Shear

#571
20190167800
2019-06-06

Lipids and compositions for the delivery of therapeutics

#572
20190161757
2019-05-30

Reduced size self-delivering RNAI compounds

#573
20190144864
2019-05-16

MicroRNA Compounds and Methods for Modulating MIR-122

#574
20190144858
2019-05-16

Compositions and methods for modulating neuronal excitability and motor behavior

#575
20190136234
2019-05-09

Oligomer-conjugate complexes and their use

#576
20190127737
2019-05-02

SINGLE-STRANDED RNAI OLIGONUCLEOTIDES TARGETING APOC-III

#577
20190127682
2019-05-02

Nucleic acid and other compositions and methods for the modulation of cell membranes

#578
20190119683
2019-04-25

Single-stranded oligonucleotide

#579
20190119674
2019-04-25

COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE

#580
20190106694
2019-04-11

GNAQ targeted dsRNA compositions and methods for inhibiting expression

#581
20190106379
2019-04-11

NOVEL CYCLIC CATIONIC LIPIDS AND METHODS OF USE

#582
20190093106
2019-03-28

Compositions and methods for treating diabetic retinopathy

#583
20190091254
2019-03-28

Treatment of cancer by systemic administration of Dbait molecules

#584
20190085332
2019-03-21

DNA aptamers specific to CD2000R1 and their therapeutic uses

#585
20190077879
2019-03-14

Conjugates enhancing total cellular accumulation

#586
20190071672
2019-03-07

Pharmaceutical Composition

#587
20190062744
2019-02-28

Oligomeric compounds and compositions for use in modulation of small non-coding RNAs

#588
20190062437
2019-02-28

Nucleic acid-polypeptide compositions and uses thereof

#589
20190062436
2019-02-28

Nucleic acid-polypeptide compositions and uses thereof

#590
20190060488
2019-02-28

Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety

#591
20190060347
2019-02-28

Microbubble complexes and methods of use

#592
20190055554
2019-02-21

COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION

#593
20190048344
2019-02-14

CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION

#594
20190048341
2019-02-14

Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA

#595
20190032051
2019-01-31

NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY

#596
20190015330
2019-01-17

Liposomes comprising a calcium phosphate-containing precipitate

#597
20190010502
2019-01-10

COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MUTANT EGFR GENE

#598
20190008976
2019-01-10

Compounds and methods for trans-membrane delivery of molecules

#599
20190002885
2019-01-03

Anti-ADAM33 oligonucleotides and related methods

#600
20190002881
2019-01-03

RNA-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor